Retatrutide , a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, is in clinical development
Beyond weight loss, the mechanistic reasons these may help in T1D include: reduced glucagon output, reduced hepatic glucose output, improved satiety signalling, and slower gastric emptying (which can improve matching when handled carefully)
Track your intake until you're confident you're hitting targets
You will use a small, insulin-style needle to inject the medication into the fatty tissue of your abdomen, thigh, or upper arm, rotating the injection site each time
The France Info feature reflects a growing international curiosity about how the United States is handling a wave of new GLP-1-based medications such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro)